Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29034485 | 0.86 | ALPI (0.56) | SLC7A5MMP2HDAC8 | |
| SCHEMBL2800996 | 0.86 | ALPI (0.56) | SLC7A5MMP2HDAC8 | |
| SCHEMBL28149830 | 0.84 | ALOX15 (0.59) | SLC7A5ALDH1A1SLC6A2ESR1 | |
| SCHEMBL13396365 | 0.82 | SLC7A5 (0.50) | SLC7A5MMP2ALDH1A1HDAC8TAAR1 | |
| SCHEMBL1832905 | 0.80 | SLC7A5 (0.48) | SLC7A5MMP2ALDH1A1HDAC8 | |
| SCHEMBL13396364 | 0.80 | SLC7A5 (0.48) | SLC7A5MMP2ALDH1A1HDAC8 | |
| SCHEMBL1945444 | 0.80 | SLC7A5 (0.48) | SLC7A5MMP2ALDH1A1HDAC8 | |
| SCHEMBL14060350 | 0.80 | SLC7A5 (0.48) | SLC7A5MMP2ALDH1A1HDAC8TAAR1 | |
| SCHEMBL27680265 | 0.80 | SLC7A5 (0.67) | SLC7A5HDAC8TAAR1SLC6A2ESR1 | |
| SCHEMBL4453960 | 0.80 | SLC7A5 (0.67) | SLC7A5HDAC8TAAR1SLC6A2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113105525-B | Material with function of enriching nitrotyrosine peptide fragments and preparation method and application thereof | 湖南师范大学 | 2023-11-24 | — | — | CN | claimed |
| EP-2859354-B1 | NITRATED CARDIAC TROPONIN I AS A BIOMARKER OF CARDIAC ISCHEMIA | FLEURY S A (BR) | 2016-09-14 | — | — | EP | claimed |
| CN-105934240-A | Hybrid, composition containing the hybrid, preparation method and use thereof | 安杰瑞姆生物科学公司 | 2016-09-07 | — | — | CN | claimed |
| EP-2235539-B1 | USE OF A PROTEIN OR NITRATED PEPTIDE SEQUENCE FOR IMPLEMENTING A DIAGNOSIS METHOD | Université Joseph Fourier (FR) | 2016-08-31 | — | — | EP | claimed |
| EP-2235539-A2 | USE OF A PROTEIN OR NITRATED PEPTIDE SEQUENCE FOR IMPLEMENTING A DIAGNOSIS METHOD | Université Joseph Fourier (FR) | 2010-10-06 | — | — | EP | claimed |
| WO-2009112670-A2 | USE OF A PROTEIN OR NITRATED PEPTIDE SEQUENCE FOR IMPLEMENTING A DIAGNOSIS METHOD | UNIVERSITE JOSEPH FOURIER (FR) | 2009-09-17 | — | — | WO | claimed |
| EP-3319984-B1 | TAU-BINDING ANTIBODIES | UCB Biopharma SRL (BE) | 2026-03-11 | — | — | EP | disclosed |
| CN-116712454-B | Multi-dimensional cisplatin nephrotoxicity reducing nanoparticle as well as preparation method and application thereof | 中南大学 | 2025-06-17 | — | — | CN | disclosed |
| CN-119876395-A | DNA methylation marker composition for screening gastric cancer | 上海荧测生物科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-3689820-B1 | SENSORS COMPRISING MESOPOROUS SILICA PARTICLES | KIM YOUNGDO (KR) | 2025-03-19 | — | — | EP | disclosed |
| WO-2024013024-A1 | BIOSENSOR FOR DETECTION OF TSH LEVELS | HEI THERAPEUTICS APS (DK) | 2024-01-18 | — | — | WO | disclosed |
| EP-4306947-A1 | BIOSENSOR FOR DETECTION OF TSH LEVELS | HEI Therapeutics ApS (DK) | 2024-01-17 | — | — | EP | disclosed |
| CN-113105525-B | Material with function of enriching nitrotyrosine peptide fragments and preparation method and application thereof | 湖南师范大学 | 2023-11-24 | — | — | CN | disclosed |
| CN-1511258-A | Method and kit for following neurodegenerative diseases | GEMAC | 2004-07-07 | — | — | CN | disclosed |
| WO-2003076946-A2 | DETECTION OF SPECIFIC NITRATED PROTEIN MARKERS | UNIVERSITE DE LIEGE (BE) | 2003-09-18 | — | — | WO | disclosed |
| US-6586467-B2 | Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus | ARRAY BIOPHARMA INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1301474-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | Array Biopharma Inc. (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020040003-A1 | Preparation of phosphatase inhibitors | ARRAY BIOPHARMA INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002004412-A2 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-1998051307-A1 | METHODS FOR TREATING INFLAMMATION, INFLAMMATORY DISEASES, ARTHRITIS AND STROKE USING pADPRT INHIBITORS | OCTAMER, INC. (US) | 1998-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040003-A1 | Preparation of phosphatase inhibitors | PTPRS, PTPRO, PTPRR | SLC7A5 2995/4885MMP2 1609/4885ALDH1A1 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.